How should a family physician treat insomnia in adult patients, including sleep hygiene, cognitive‑behavioral therapy for insomnia (CBT‑I), and short‑term pharmacologic options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treating Insomnia in Family Practice

All adult patients with chronic insomnia should receive cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, and pharmacologic therapy should only be added short-term through shared decision-making if CBT-I fails. 1

Initial Treatment Approach

Start with CBT-I as the mandatory first-line intervention for all adults with chronic insomnia disorder 1. This is a strong recommendation based on moderate-quality evidence showing improved sleep outcomes (reduced sleep onset latency, wake after sleep onset, improved sleep efficiency) and global outcomes (remission rates, treatment response) with minimal harms 1.

What CBT-I Actually Includes:

  • Cognitive therapy addressing dysfunctional beliefs about sleep
  • Behavioral interventions: sleep restriction and stimulus control
  • Sleep hygiene education (though insufficient alone) 2

Delivery Methods (All Effective):

  • In-person individual or group therapy
  • Telephone-based modules
  • Web-based/digital programs 3, 4
  • Self-help books 1

Critical point: CBT-I can be performed in primary care settings 1. Digital CBT-I is increasingly accessible and addresses the availability barrier 3, 4.

When to Add Pharmacotherapy

Only consider medications if CBT-I alone fails 1. Use shared decision-making discussing benefits, harms, and costs of short-term use only 1.

Evidence-Based Medication Options:

For sleep initiation and maintenance:

  • Low-dose doxepin (evidence-based option) 5
  • Dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) - effective for both sleep onset and maintenance, safe up to 3 months 6, 7
  • Melatonin receptor agonists (ramelteon) - safer but limited effectiveness 6

For short-term use (≤4 weeks):

  • Z-drugs (zolpidem, eszopiclone) - improved sleep outcomes in general population 1, safe in depression/anxiety but avoid in older adults due to cognitive impairment, falls, and fractures 1
  • Benzodiazepines - short-term only (up to 4 weeks), triazolam for sleep-onset/middle-of-night insomnia 7

Off-label but commonly used:

  • Trazodone - most prescribed off-label treatment, effective for sleep initiation and maintenance, lacks abuse potential 3

Critical Warnings:

The FDA specifically warns about serious adverse effects with hypnotics including:

  • Dementia and fractures (observational data) 1
  • Cognitive and behavioral changes
  • Driving impairment and motor vehicle accidents 1
  • Lower doses required for women, older adults, and debilitated patients 1

What NOT to Use:

  • Antihistamines (diphenhydramine) - lacking evidence except doxylamine effective up to 4 weeks only 6
  • Antipsychotics - not recommended 7
  • Commonly prescribed older medications (diphenhydramine, trazodone) - inadequately studied in trials despite widespread use 1

Dosing Strategy

Use the lowest effective dose for the shortest duration 3. Consider:

  • As-needed basis rather than nightly 3
  • Non-nightly use for patients not requiring daily treatment 7
  • Maximum 6 weeks for nightly use 3
  • Up to 3 months for orexin receptor antagonists 7

Special Populations

Older adults:

  • More likely to have sleep maintenance problems than sleep onset issues 1
  • Avoid benzodiazepines and Z-drugs due to falls, fractures, cognitive impairment 1
  • Consider orexin receptor antagonists (safe with mild cognitive impairment) 3

Patients with psychiatric comorbidities:

  • Z-drugs are safe and effective in depression/anxiety 3
  • Orexin receptor antagonists require further study in psychiatric populations 3

Common Pitfalls to Avoid

  1. Skipping CBT-I and going straight to medications - violates evidence-based guidelines 1
  2. Long-term hypnotic use - FDA recommends short-term only, but many patients continue extended periods 1
  3. Using benzodiazepines/Z-drugs in older adults - high risk of serious adverse events 1
  4. Relying on sleep hygiene alone - necessary but insufficient as monotherapy 2
  5. Not screening for contributing factors: sleep apnea, restless legs syndrome, narcolepsy, medications, medical/psychiatric diagnoses, substance use 3

Documentation Requirements

Document the specific insomnia type:

  • Difficulty falling asleep (sleep onset latency)
  • Difficulty maintaining sleep (wake after sleep onset)
  • Early morning awakening
  • Resulting functional impairment
  • Duration (short-term vs. persistent ≥3 months) 3

References

Research

Insomnia in ambulatory care: A clinical review.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2025

Research

Insomnia.

Continuum (Minneapolis, Minn.), 2026

Research

Treatment of Chronic Insomnia in Adults.

American family physician, 2024

Research

Insomnia disorder.

Minerva medica, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.